BPC-157 dosing protocols
Reported BPC-157 dosing patterns for general recovery, acute injury, and gut-focused use — with reconstitution math and cycling guidance.
Updated May 7, 2026 · 3 min read
Reported BPC-157 protocols cluster into three patterns: general recovery, targeted injury, and gut-focused. Doses are most often given subcutaneously, in mcg-range volumes that fit easily on an insulin syringe. This is education, not medical advice — talk to a clinician before starting any peptide.
Quick reference
| Goal | Daily dose | Cadence | Duration |
|---|---|---|---|
| General recovery | 250 mcg | Once daily | 4–6 weeks |
| Acute injury (subQ near site) | 250 mcg twice daily | Twice daily | 6–8 weeks |
| Gut / GI focus | 250–500 mcg | Once daily, oral or SubQ | 4–8 weeks |
Across protocols, the daily total typically lands between 250 mcg and 1 mg. Doses above that haven't been shown to scale benefit and are more likely to amplify mild lethargy or headaches.
How to convert mg to syringe units
BPC-157 ships lyophilized. The conversion most people use:
5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL.
A 250 mcg dose → 0.1 mL → 10 units on a U-100 insulin syringe.
A 500 mcg dose → 0.2 mL → 20 units.
The reconstitution calculator handles the math live — including which insulin-syringe size (30, 50, or 100 unit) gives the cleanest measurement.
Cycling
Most users run BPC-157 in 4–8 week cycles rather than indefinitely. The reasoning:
- The pre-clinical record is on healing and recovery, not chronic preventive use
- Continuous angiogenic signaling has theoretical (not demonstrated) cancer concerns
- Your goal is usually a specific recovery target — once you're there, you stop
A common pattern: 6 weeks on at 250 mcg/day, then 4–6 weeks off. Reassess. If the issue is resolved, no need to restart.
Site selection
For systemic recovery, any standard SubQ site works (abdomen, thigh, upper arm). For acute injury work, the most-reported pattern is to inject near but not into the affected tissue:
- Achilles tendon: subq into the calf, 1–2 inches from the tendon
- Knee: subq into the surrounding tissue, not directly into the joint capsule
- Lower back: paraspinal subq, not deep intramuscular
Direct injection into a tendon or joint is not the standard protocol and carries injection-trauma risk. Stay subQ unless a qualified clinician is doing the injection.
Oral BPC-157
Unlike most peptides, BPC-157 has some oral bioavailability — it's stable in stomach acid by design. The reported pattern for gut-focused use:
- 250–500 mcg/day dissolved in water, on an empty stomach
- Often 4–6 weeks for IBD, GERD, or ulcer-related goals
- Some users do morning oral + evening SubQ for combined systemic and GI effect
For musculoskeletal goals, injection is more reported and reportedly more effective. For gut-only goals, oral is reasonable.
Common dosing mistakes
The most common reported errors:
- Dosing too high. Doubling the dose doesn't double the result. 250 mcg/day is enough for most general-recovery cases.
- Running indefinitely. Cycle. Reassess. Don't normalize a continuous signaling drug.
- Inconsistent timing. Daily-at-the-same-time matters more than dose size for results.
- Skipping reconstitution math. Eyeballing a vial is how dosing errors happen.